Bayer: signs license agreement with US biotech firm
(CercleFinance.com) - German drugmaker Bayer reached an agreement with US biotech firm Dewpoint Therapeutics to research new treatments for cardiovascular and gynecological diseases.
Bayer and Dewpoint today announced an option, research and license agreement worth up to 100 million dollars that will leverage Dewpoint's platform for biomolecular condensates and Bayer's small molecule compound library.
Under the terms of the deal, Bayer will have the option to exclusively license a specific number of novel therapeutics derived from research activities.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Bayer and Dewpoint today announced an option, research and license agreement worth up to 100 million dollars that will leverage Dewpoint's platform for biomolecular condensates and Bayer's small molecule compound library.
Under the terms of the deal, Bayer will have the option to exclusively license a specific number of novel therapeutics derived from research activities.
Copyright (c) 2019 CercleFinance.com. All rights reserved.